Real-world study of olaparib plus abiraterone for advanced prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial is for people with advanced prostate cancer (mCRPC) who are already taking the combination of olaparib and abiraterone. It will look at how these two medicines work together in real-world practice.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with prostate cancer that has spread to other parts of the body and is not responding to standard hormone therapy (mCRPC).
- You have already started taking the combination of olaparib and abiraterone after the study started.
- You have not been in another clinical trial for prostate cancer within the last 30 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how men with advanced prostate cancer that has spread are doing while taking the drug olaparib. Researchers want to understand how well the drug works and what happens to patients over time.
This trial combines radiation therapy with two drugs (fluzopanib and abiraterone acetate) to treat men with metastatic castration-resistant prostate cancer that hasn't been treated yet. The goal is to see if this triple approach helps slow the cancer's growth.
This trial tests a new combination of two drugs (xaluritamig plus abiraterone) for men with a type of advanced prostate cancer that is no longer responding to hormone therapy but has not yet been treated with chemotherapy. The goal is to see if this combination works better than the standard options your doctor might choose.
This trial studies how well the combination of olaparib and abiraterone works for men with advanced prostate cancer that has stopped responding to hormone therapy. If you are already taking or planning to take this combination, researchers want to learn more about its long-term benefits and safety.
This trial studies how well olaparib works for men with metastatic castration-resistant prostate cancer that has a BRCA mutation. It looks at results from real-world use, not a controlled study.
This trial tests a new drug combination (BL-B01D1) for men with advanced prostate cancer that has stopped responding to hormone therapy. The study aims to see if this treatment can slow cancer growth and improve survival.
Hear when a new Metastatic Castration-resistant Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.